Valuation: VolitionRx Limited

Market Cap 3.74M 3.28M 3.08M 2.82M 5.27M 358M 5.31M 37.04M 14.36M 183M 14.04M 13.73M 592M P/E 2026 *
-0.13x
P/E 2027 * -0.26x
Enterprise Value 3.74M 3.28M 3.08M 2.82M 5.27M 358M 5.31M 37.04M 14.36M 183M 14.04M 13.73M 592M EV / Sales 2026 *
1.37x
EV / Sales 2027 * 0.4x
Free-Float
96.42%
Yield 2026 *
-
Yield 2027 * -
1 day-10.71%
1 week-13.90%
Current month-45.45%
1 month-39.46%
3 months-80.44%
6 months-94.24%
Current year-95.37%
1 week 0.24
Extreme 0.2353
0.3
1 month 0.24
Extreme 0.2353
0.72
Current year 0.24
Extreme 0.2353
7.73
1 year 0.24
Extreme 0.2353
14.8
3 years 0.24
Extreme 0.2353
24.6
5 years 0.24
Extreme 0.2353
82.8
10 years 0.24
Extreme 0.2353
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Director/Board Member 55 06/10/2011
Director/Board Member 77 06/10/2011
Director/Board Member 64 09/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
17/3/26
Concord International, Inc.
OtherCompany 0 0% -
17/3/26 Tax

Executive/Senior Manager

5,251 0.0039%
17/3/26 Tax

General Counsel

7,003 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-10.71%-13.90%-98.04%-98.43% 3.74M
-3.90%+4.26%+397.11%+125.17% 4.82B
-0.93%+0.11%+98.85%+445.28% 4.48B
-1.21%+11.29%+25.46%+90.68% 3.49B
-1.32%+3.88%+257.29%+628.14% 2.92B
+0.48%+21.07%-12.68%-17.58% 2.51B
-5.56%+12.40%+55.24% - 1.77B
-0.58%+5.43%+28.30%+61.14% 1.15B
-2.28%+6.21%+165.15%-21.88% 1.11B
+5.08%+1.02%-13.13%+84.39% 598M
Average -2.14%+6.82%+90.35%+144.10% 2.28B
Weighted average by Cap. -1.81%+9.50%+151.93%+227.78%

Financials

2026 *2027 *
Net sales 2.72M 2.39M 2.25M 2.05M 3.84M 261M 3.87M 26.99M 10.46M 133M 10.23M 10M 431M 9.27M 8.14M 7.65M 7M 13.07M 888M 13.17M 91.91M 35.63M 453M 34.83M 34.07M 1.47B
Net income -22.25M -19.53M -18.36M -16.78M -31.36M -2.13B -31.6M -221M -85.48M -1.09B -83.56M -81.73M -3.52B -18.42M -16.17M -15.2M -13.89M -25.96M -1.76B -26.15M -183M -70.76M -900M -69.17M -67.65M -2.92B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a company focused on advancing the science of epigenetics. The Company is focused on saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its products are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
57
Date Price Change Volume
24/09/26 USD 0.2372 -9.88% 1,991,551
22/09/26 USD 0.2632 -0.64% 1,717,967
21/09/26 USD 0.2649 +1.88% 1,859,474
18/09/26 USD 0.2600 -8.74% 4,368,077
17/09/26 USD 0.2849 +3.64% 28,229,427
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2632USD
Average target price
13.62USD
Spread / Average Target
+5,075.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock